OncoMarks

Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC [OptiTROP-Lung06]

After a median follow-up of 9.7 months, the median progression-free survival (PFS) by blinded independent central review was significantly longer with sacitu...

Lung Cancer - SCLC - Extensive

Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer [DeLLphi-305]

At a median follow-up of 15.9 months (tarlatamab–durvalumab) and 16.1 months (durvalumab), the median overall survival was 21.1 months (95% CI, 20.8 to not...

Bladder Tumors - Locally-Advanced

Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer [VOLGA]

At a median follow-up of 22.9 months, estimated event-free survival at 24 months was 63.5% in the durvalumab–EV group versus 45.1% in the control group (HR...

Breast Cancer - Metastatic - Her2+

Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer [HEALER]

At a prespecified interim analysis with 401 events and a median follow-up of 21.0 months, anbenitamab plus HB1801 demonstrated significantly superior progres...

Breast Cancer - Metastatic - GeneralProstate Cancer - mCRPC

2020

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer

Of 263 patients (160 breast cancer, 103 CRPC), 133 were randomised to 4-weekly and 130 to 12-weekly BTA therapy. The primary outcome, change in HRQoL physica...

View Details 2026/10/23 Ali Aqamolaei

Prostate Cancer - mCRPC

View Details 2026/10/23 Ali Aqamolaei

Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer

With a median follow-up of 58 months and 317 deaths reported, the final OS analysis demonstrated a statistically significant improvement in OS for the enzalu...

Library

Top medical reference books

Trending Trials

Most liked trials

Colorectal Cancer - Metastatic

Breast Cancer - Metastatic - HR+

Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial

At a median follow-up of 34.9 months in the modified intention-to-treat (mITT) population (n=92), the 1-year freedom from local progression was 83.0% (95% CI...

View Details 2026/09/26 Shakiba Sheikholeslami

View Details 2026/07/30 Ali Aqamolaei

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial

At median follow-up of 23.5 months, median progression-free survival was 16.8 months (95% CI 14.7–19.4) with camizestrant plus CDK4/6 inhibitor versus 9.2 ...

Breast Cancer - Early StageBreast Cancer - Locally-Advanced

Breast Cancer Atlas for Radiation Therapy Planning: Consensus Definitions

This consensus guideline provides detailed anatomical boundaries and contouring principles for breast cancer radiation therapy planning. For intact breast af...

View Details 2026/06/06 Ali Aqamolaei

Colorectal Cancer - Early StageColorectal Cancer - Locally-Advanced

View Details 2026/05/30 Ali Aqamolaei

Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial

With a median follow-up of 113 months and 1,255 OS events, 5-year OS for 3 versus 6 months of treatment was 82.4% in both groups (HR, 0.96 95% CI, 0.86 to 1....

Esophageal Cancer - Locally-Advanced

2025

Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial

Two-year overall survival was non-inferior for active surveillance (74%) compared to standard surgery (71%) in modified intention-to-treat analysis, with the...

View Details 2026/05/29 Ali Aqamolaei

Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC [OptiTROP-Lung06]

After a median follow-up of 9.7 months, the median progression-free survival (PFS) by blinded independent central review was significantly longer with sacitu...

Breast Cancer - Early StageBreast Cancer - Radiation - Post BCS

OncoMarks Favorites

Most bookmarked trials across users

2023

Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer [LUMINA]

At 5 years after enrollment, the cumulative incidence of local recurrence in the ipsilateral breast was 2.3% (90% CI, 1.3 to 3.8; 95% CI, 1.2 to 4.1), meetin...

View Details 2026/09/04 Ali Aqamolaei

Breast Cancer - Metastatic - HR+

View Details 2026/07/30 Ali Aqamolaei

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial

At median follow-up of 23.5 months, median progression-free survival was 16.8 months (95% CI 14.7–19.4) with camizestrant plus CDK4/6 inhibitor versus 9.2 ...

Colorectal Cancer - Early StageColorectal Cancer - Locally-Advanced

International consensus guidelines on Clinical Target Volume delineation in rectal cancer (Atlas)

View Details 2026/06/05 Ali Aqamolaei

Colorectal Cancer - Early StageColorectal Cancer - Locally-Advanced

View Details 2026/05/30 Ali Aqamolaei

Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial

With a median follow-up of 113 months and 1,255 OS events, 5-year OS for 3 versus 6 months of treatment was 82.4% in both groups (HR, 0.96 95% CI, 0.86 to 1....

Esophageal Cancer - Locally-Advanced

2025

Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial

Two-year overall survival was non-inferior for active surveillance (74%) compared to standard surgery (71%) in modified intention-to-treat analysis, with the...

View Details 2026/05/29 Ali Aqamolaei

Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC [OptiTROP-Lung06]

After a median follow-up of 9.7 months, the median progression-free survival (PFS) by blinded independent central review was significantly longer with sacitu...

Highlights

Notable recent publications

Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC [OptiTROP-Lung06]

After a median follow-up of 9.7 months, the median progression-free survival (PFS) by blinded independent central review was significantly longer with sacitu...

Lung Cancer - SCLC - Extensive

Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer [DeLLphi-305]

At a median follow-up of 15.9 months (tarlatamab–durvalumab) and 16.1 months (durvalumab), the median overall survival was 21.1 months (95% CI, 20.8 to not...

Bladder Tumors - Locally-Advanced

Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer [VOLGA]

At a median follow-up of 22.9 months, estimated event-free survival at 24 months was 63.5% in the durvalumab–EV group versus 45.1% in the control group (HR...

Breast Cancer - Metastatic - Her2+

Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer [HEALER]

At a prespecified interim analysis with 401 events and a median follow-up of 21.0 months, anbenitamab plus HB1801 demonstrated significantly superior progres...

Prostate Cancer - mCRPC

View Details 2026/10/23 Ali Aqamolaei

Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer

With a median follow-up of 58 months and 317 deaths reported, the final OS analysis demonstrated a statistically significant improvement in OS for the enzalu...

Prostate Cancer - mHSPC